|
1
|
Maemondo M, Inoue A, Kobayashi K, Sugawara
S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I,
et al: Gefitinib or chemotherapy for non-small-cell lung cancer
with mutated EGFR. N Engl J Med. 362:2380–2388. 2010.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Mitsudomi T, Morita S, Yatabe Y, Negoro S,
Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, et
al: Gefitinib versus cisplatin plus docetaxel in patients with
non-small-cell lung cancer harbouring mutations of the epidermal
growth factor receptor (WJTOG3405): An open label, randomised phase
3 trial. Lancet Oncol. 11:121–128. 2010.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Park K, Tan EH, O'Byrne K, Zhang L, Boyer
M, Mok T, Hirsh V, Yang JC, Lee KH, Lu S, et al: Afatinib versus
gefitinib as first-line treatment of patients with EGFR
mutation-positive non-small-cell lung cancer (LUX-Lung 7): A phase
2B, open-label, randomised controlled trial. Lancet Oncol.
17:577–589. 2016.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Mok TS, Cheng Y, Zhou X, Lee KH, Nakagawa
K, Niho S, Lee M, Linke R, Rosell R, Corral J, et al: Improvement
in overall survival in a randomized study that compared dacomitinib
with gefitinib in patients with advanced non-small-cell lung cancer
and EGFR-activating mutations. J Clin Oncol. 36:2244–2250.
2018.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Soria JC, Ohe Y, Vansteenkiste J,
Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura
F, Nogami N, Kurata T, et al: Osimertinib in untreated EGFR-mutated
advanced non-small-cell lung cancer. N Engl J Med. 378:113–125.
2018.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Ramalingam SS, Vansteenkiste J, Planchard
D, Cho BC, Gray JE, Ohe Y, Zhou C, Reungwetwattana T, Cheng Y,
Chewaskulyong B, et al: Overall survival with osimertinib in
untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 382:41–50.
2020.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Yang CY, Liao WY, Ho CC, Chen KY, Tsai TH,
Hsu CL, Su KY, Chang YL, Wu CT, Hsu CC, et al: Association between
programmed death-ligand 1 expression, immune microenvironments, and
clinical outcomes in epidermal growth factor receptor mutant lung
adenocarcinoma patients treated with tyrosine kinase inhibitors.
Eur J Cancer. 124:110–122. 2020.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Inomata M, Azechi K, Takata N, Hayashi K,
Tokui K, Taka C, Okazawa S, Kambara K, Imanishi S, Miwa T, et al:
Association of tumor PD-L1 expression with the T790M mutation and
progression-free survival in patients with EGFR-mutant non-small
cell lung cancer receiving EGFR-TKI therapy. Diagnostics (Basel).
10(1006)2020.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Yoon BW, Chang B and Lee SH: High PD-L1
Expression is Associated with unfavorable clinical outcome in
EGFR-mutated lung adenocarcinomas treated with targeted therapy.
Onco Targets Ther. 13:8273–8285. 2020.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Sakata Y, Sakata S, Oya Y, Tamiya M,
Suzuki H, Shibaki R, Okada A, Kobe H, Matsumoto H, Yokoi T, et al:
Osimertinib as first-line treatment for advanced epidermal growth
factor receptor mutation-positive non-small-cell lung cancer in a
real-world setting (OSI-FACT). Eur J Cancer. 159:144–153.
2021.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Yoshimura A, Yamada T, Okuma Y, Fukuda A,
Watanabe S, Nishioka N, Takeda T, Chihara Y, Takemoto S, Harada T,
et al: Impact of tumor programmed death ligand-1 expression on
osimertinib efficacy in untreated EGFR-mutated advanced non-small
cell lung cancer: A prospective observational study. Transl Lung
Cancer Res. 10:3582–3593. 2021.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Shiozawa T, Numata T, Tamura T, Endo T,
Kaburagi T, Yamamoto Y, Yamada H, Kikuchi N, Saito K, Inagaki M, et
al: Prognostic implication of PD-L1 expression on osimertinib
treatment for EGFR-mutated non-small cell lung cancer. Anticancer
Res. 42:2583–2590. 2022.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Hsu KH, Tseng JS, Yang TY, Chen KC, Su KY,
Yu SL, Chen JJW, Huang YH and Chang GC: PD-L1 strong expressions
affect the clinical outcomes of osimertinib in treatment naive
advanced EGFR-mutant non-small cell lung cancer patients. Sci Rep.
12(9753)2022.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Inomata M, Kawashima Y, Saito R, Morinaga
D, Nogawa H, Sato M, Suzuki Y, Yanagisawa S, Kikuchi T, Jingu D, et
al: A retrospective study of the efficacy of combined EGFR-TKI plus
VEGF inhibitor/cytotoxic therapy vs. EGFR-TKI monotherapy for
PD-L1-positive EGFR-mutant non-small cell lung cancer: North Japan
Lung Cancer Study Group 2202. Oncol Lett. 26(334)2023.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Mok TS, Wu YL, Ahn MJ, Garassino MC, Kim
HR, Ramalingam SS, Shepherd FA, He Y, Akamatsu H, Theelen WS, et
al: Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung
cancer. N Engl J Med. 376:629–640. 2017.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Prelaj A, Tay R, Ferrara R, Chaput N,
Besse B and Califano R: Predictive biomarkers of response for
immune checkpoint inhibitors in non-small-cell lung cancer. Eur J
Cancer. 106:144–159. 2019.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Shirasawa M, Yoshida T, Shimoda Y,
Takayanagi D, Shiraishi K, Kubo T, Mitani S, Matsumoto Y, Masuda K,
Shinno Y, et al: Differential immune-related microenvironment
determines programmed cell death protein-1/programmed death-ligand
1 blockade efficacy in patients with advanced NSCLC. J Thorac
Oncol. 16:2078–2090. 2021.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Chen N, Fang W, Zhan J, Hong S, Tang Y,
Kang S, Zhang Y, He X, Zhou T, Qin T, et al: Upregulation of PD-L1
by EGFR activation mediates the immune escape in EGFR-driven NSCLC:
Implication for optional immune targeted therapy for NSCLC patients
with EGFR mutation. J Thorac Oncol. 10:910–923. 2015.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Ota K, Azuma K, Kawahara A, Hattori S,
Iwama E, Tanizaki J, Harada T, Matsumoto K, Takayama K, Takamori S,
et al: Induction of PD-L1 expression by the EML4-ALK oncoprotein
and downstream signaling pathways in non-small cell lung cancer.
Clin Cancer Res. 21:4014–4021. 2015.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Sumimoto H, Takano A, Teramoto K and Daigo
Y: RAS-mitogen-activated protein kinase signal is required for
enhanced PD-L1 expression in human lung cancers. PLoS One.
11(e0166626)2016.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Taniguchi H, Yamada T, Wang R, Tanimura K,
Adachi Y, Nishiyama A, Tanimoto A, Takeuchi S, Araujo LH, Boroni M,
et al: AXL confers intrinsic resistance to osimertinib and advances
the emergence of tolerant cells. Nat Commun. 10(259.
20190116)2019.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Yoshimura A, Yamada T, Serizawa M, Uehara
H, Tanimura K, Okuma Y, Fukuda A, Watanabe S, Nishioka N, Takeda T,
et al: High levels of AXL expression in untreated EGFR-mutated
non-small cell lung cancer negatively impacts the use of
osimertinib. Cancer Sci. 114:606–618. 2023.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Tsukita Y, Fujino N, Miyauchi E, Saito R,
Fujishima F, Itakura K, Kyogoku Y, Okutomo K, Yamada M, Okazaki T,
et al: Axl kinase drives immune checkpoint and chemokine signalling
pathways in lung adenocarcinomas. Mol Cancer. 18(24)2019.PubMed/NCBI View Article : Google Scholar
|
